ABL Bio (298380) announced on the 19th that it will present preclinical data for its bispecific antibody-drug conjugates (ADCs) 'ABL206' and 'ABL209' as posters at the American Association for Cancer Research (AACR) Annual Meeting. The AACR conference will be held at the San Diego Convention Center in California from April 17-22 (local time).
ABL Bio's U.S. subsidiary Neok Bio recently received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for Phase 1 clinical trials of ABL206 and ABL209. ABL206 targets both B7-H3 and ROR1, while ABL209 targets both EGFR and MUC1. Both compounds use topoisomerase 1 inhibitor-based payloads.
According to the abstracts, in preclinical studies ABL206 demonstrated enhanced efficacy and safety compared to monospecific ADCs targeting either ROR1 or B7-H3 in both in-vitro and in-vivo experiments. Good Laboratory Practice (GLP) toxicity studies in non-human primates also confirmed generally favorable tolerability. ABL209 was shown to mitigate EGFR-related toxicity while maintaining potent anti-tumor activity.
"ABL206 and ABL209 have secured promising preclinical data as next-generation ADCs," said Lee Sang-hoon, CEO of ABL Bio. "Neok Bio, which is leading clinical development, has established optimal clinical strategies with ADC development experts and aims to release Phase 1 clinical data in early next year."
